WeChat-Based Digital Therapy to Improve Fluid Intake in Kidney Stone Patients: Study Protocol
Launched by THE UNIVERSITY OF HONG KONG · May 21, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The study outcomes will be reported to adhere to the guidelines outlined in the Consolidated Standards of Reporting Trials (CONSORT) 2010 statements. Reporting measures of central tendency (mean, median) and dispersion (standard deviation, range) for continuous variables, as well as frequencies and percentages for categorical variables. Statistical tests such as a t-test and chi-square test will be employed for continuous and categorical variables within two groups. The principal analysis will compare the fluid intake volume between the intervention and control groups using the t-test. Seco...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • With a history of urinary calculi and having received urolithiasis surgery before
- • 24-hour fluid intake \< 2500 ml
- • Age ≥ 18 years old
- • Able to use WeChat daily
- • Able to read and write informed consent
- Exclusion Criteria:
- • Participants with obstructive uropathy, chronic urosepsis, renal failure, and renal tubular acidosis
- • Participants with congestive heart failure, psychiatric conditions, pregnancy, and primary hyperparathyroidism
- • Participants experienced complicated urolithiasis surgery.
- • History of recurrent UTI (urinary tract infection) (\>3/year)
- • Medication use increases stone risk.
- • Participants with physical disabilities
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenzhen, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported